[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tempus AI Cl A (TEM)

Tempus AI Cl A (TEM)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 9,062,646
  • Shares Outstanding, K 179,565
  • Annual Sales, $ 1,272 M
  • Annual Income, $ -245,030 K
  • EBIT $ -269 M
  • EBITDA $ -162 M
  • 60-Month Beta 3.99
  • Price/Sales 7.24
  • Price/Cash Flow N/A
  • Price/Book 22.10

Options Overview Details

View History
  • Implied Volatility 73.70% (+0.37%)
  • Historical Volatility 58.48%
  • IV Percentile 47%
  • IV Rank 37.84%
  • IV High 95.11% on 10/10/25
  • IV Low 60.65% on 12/10/25
  • Expected Move (DTE 5) 3.42 (6.77%)
  • Put/Call Vol Ratio 0.21
  • Today's Volume 63,695
  • Volume Avg (30-Day) 28,425
  • Put/Call OI Ratio 0.59
  • Today's Open Interest 357,370
  • Open Int (30-Day) 322,597
  • Expected Range 47.05 to 53.89

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.41
  • Number of Estimates 4
  • High Estimate $-0.31
  • Low Estimate $-0.50
  • Prior Year $-0.36
  • Growth Rate Est. (year over year) -13.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.62 +18.42%
on 05/19/26
56.41 -10.53%
on 05/05/26
+0.45 (+0.90%)
since 04/29/26
3-Month
41.73 +20.94%
on 03/30/26
58.04 -13.04%
on 04/16/26
-2.78 (-5.22%)
since 02/27/26
52-Week
41.73 +20.94%
on 03/30/26
104.32 -51.62%
on 10/09/25
-2.73 (-5.13%)
since 05/28/25

Most Recent Stories

More News
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community

Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding to catalyze clinical and technical breakthroughs...

TEM : 50.47 (-1.60%)
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the introduction of Tempus Preview, an application providing rapid, clinically...

TEM : 50.47 (-1.60%)
Tempus Announces Initial Results from its Multimodal Foundation Model Efforts for Novel and Scalable Insight Generation in Oncology

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced the latest results from its mission to build Multimodal Foundation Models at...

TEM : 50.47 (-1.60%)
Tempus Receives FDA Approval for Tumor Only xT CDx, Enabling Migration of its Entire DNA Solid Tumor Portfolio

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for a...

TEM : 50.47 (-1.60%)
Tempus Expands Next Platform to Deliver Real-Time Clinical Intelligence and Close Critical Care Gaps Across Oncology

Expanded platform delivers patient insights across six new clinical scenarios in breast, colorectal, ovarian, prostate, and urothelial cancers

TEM : 50.47 (-1.60%)
Tempus Upgrades Its Smart Physician Platform, Hub, with Next-Generation Agentic AI Architecture to Streamline Clinical Workflows

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a major technological upgrade to Tempus Hub , its AI-enabled...

TEM : 50.47 (-1.60%)
Tempus Announces 37 Abstracts Accepted for Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced that 37 abstracts have been accepted for presentation at the 2026 American...

TEM : 50.47 (-1.60%)
Tempus Launches ArteraAI Prostate Test for Metastatic Patients, Marking the First Prostate Digital Pathology Algorithm in the Tempus Ecosystem Available for Clinical Use

Tempus AI, Inc., a leader in artificial intelligence and precision medicine, today announced the clinical launch of the ArteraAI Prostate Test (mHSPC). The CLIA-certified and CAP-accredited prognostic...

TEM : 50.47 (-1.60%)
How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here

While investors are scaling back the AI-at-any-cost narrative, TEM stock brings to the table a highly speculative but enticing bullish trade.

TEM : 50.47 (-1.60%)
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a new initiative with Bristol Myers Squibb (NYSE: BMY). This collaboration...

TEM : 50.47 (-1.60%)
BMY : 57.18 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery,...

See More

Key Turning Points

3rd Resistance Point 57.69
2nd Resistance Point 55.55
1st Resistance Point 53.01
Last Price 50.47
1st Support Level 48.33
2nd Support Level 46.19
3rd Support Level 43.65

See More

52-Week High 104.32
Fibonacci 61.8% 80.41
Fibonacci 50% 73.03
Fibonacci 38.2% 65.64
Last Price 50.47
52-Week Low 41.73

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.